XML 41 R32.htm IDEA: XBRL DOCUMENT v3.25.3
Discontinued Operations and Divestiture - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Nov. 06, 2025
Aug. 29, 2025
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Gain on divestiture         $ 52,163 $ 0  
Accounts receivable from related parties     $ 121   121   $ 481
Share Purchase Agreement [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Discontinued operation consideration   $ 220,400          
Discontinued operation cash paid at closing   210,400          
Discontinued operation other receivable     10,000   $ 10,000    
Falikang [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Percentage of outstanding shares owned         51.10%    
Investment income (loss)     1,400 $ 900 $ 2,500 2,700  
Equity method investments             6,900
Accounts receivable from related parties             $ 13,900
Falikang [Member] | Collaborative Arrangement [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Revenues     165,300 42,200 $ 218,600 115,300  
Increase in revenue     118,300        
AstraZeneca [Member] | Share Purchase Agreement [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Discontinued operation cash payable at closing subject to holdbacks   10,000          
Discontinued operation hold back amount to offset final net cash adjustments   6,000          
Discontinued operation, hold back amount to satisfy any indemnity claims   4,000          
AstraZeneca [Member] | Share Purchase Agreement [Member] | Subsequent Event [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Disposal group including discontinued operation additional payment following final net cash adjustments after closing $ 400            
Discontinued operation hold back amount received as final net cash adjustments $ 6,400            
FibroGen International [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Description of discontinued operations         On February 20, 2025, the Company entered into the Share Purchase Agreement with AstraZeneca Treasury Limited, pursuant to which FibroGen and its subsidiary FibroGen China Anemia Holdings, Ltd. agreed to sell all of the issued and outstanding equity interests of FibroGen International to AstraZeneca Treasury Limited. This sale includes all of our roxadustat assets in China, including FibroGen International’s subsidiary FibroGen Beijing and its 51.1% interest in Falikang. The Company determined that FibroGen International met the “held for sale” criteria and the “discontinued operations” criteria in accordance with FASB ASC 205, Presentation of Financial Statements, as of December 31, 2024. Accordingly, the operating results related to the FibroGen International are classified as discontinued operations, and have been reflected as discontinued operations in the condensed consolidated statements of operations, while the related assets and liabilities were classified within the condensed consolidated balance sheets as held for sale for all periods presented.    
Discontinued operations name         FibroGen International    
Gain on divestiture   52,200 $ 52,163 $ 0 $ 52,163 $ 0  
FibroGen International [Member] | Share Purchase Agreement [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Discontinued operation consideration   220,400          
Discontinued operation consideration in cash   85,000          
Discontinued operation consideration transaction costs and fees   7,800          
Discontinued operation derecognition of net equity   154,900          
Discontinued operatiion cumulative currency translation adjustments   5,500          
Net Cash Held in China [Member] | Share Purchase Agreement [Member]              
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]              
Discontinued operation consideration in cash   $ 135,400